Published in AIDS Weekly, July 7th, 2003
"The DNA polymerase (POL) of Kaposi's sarcoma-associated herpesvirus (KSHV) is essential for viral DNA replication and, thus, may be considered as a viable target for anti-KSHV therapeutics," researchers in the United States explained.
"To produce large quantities of homogeneous and pure POL required for high-throughput screening (HTS) for inhibitors," D. Dorjsuren and colleagues working at Science Applications International Corporation (SAIC)-Frederick in Ft. Detrick, Maryland "generated a recombinant baculovirus vector encoding a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.